Afimetoran
As of the edition of 20 October 2026, Afimetoran is a small molecule: in active development; acts on TLR7 and TLR8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Small molecule
- Registered trials
- 11, 0 stopped early
- Disease areas
- Skin and connective tissue; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 10 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2018 to now |
| Beeline Medicines | Lead sponsor of trials | 2021 to now |